World AIDS Day 2024 CIRA Talk: "Long-acting Injectable HIV PrEP: Current Research and Implications for Access"

Clinical trials on a novel long-acting injectable form of HIV pre-exposure prophylaxis (PrEP) are currently ongoing. Findings of a trial recently presented at the AIDS 2024 Conference have demonstrated the safety and efficacy of lenacapavir, a twice-yearly injectable drug, to prevent HIV among HIV-negative cisgender women (PURPOSE 1). An interim analysis of the sister study, PURPOSE 2, involving cisgender men, transgender men, transgender women, and gender non-binary individuals, reports a reduction of HIV infections by 96%.

The 2024 World AIDS Day theme is "Take the Rights Path" that promotes fostering inclusion of all communities and removing barriers to HIV prevention and care to end AIDS globally. Join the Center for Interdisciplinary Research on AIDS (CIRA) at Yale University for a CIRA Talk event featuring a presentation by Dr. Onyema Ogbuagu that will highlight current research on long-acting injectable HIV PrEP and a discussion on implications for access to promote HIV equity. Dr. Ogbuagu, Associate Professor of Medicine and Pharmacology at Yale School Medicine, is a practicing clinician and has served as principal investigator on multiple multinational trials for HIV treatment and prevention. This webinar will be moderated by Dr. Luke Davis, Yale School of Public Health and Dr. E. Jennifer Edelman, Yale School of Medicine.